Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Doesn’t Like Crossover Design For Placebo Patients In COVID-19 Vaccine Trial

Executive Summary

Only vaccinating the placebo group would be much easier once the US FDA grants an EUA for its coronavirus vaccine, Pfizer says.

You may also be interested in...



Unblinding Plans For COVID-19 Vaccine Trials Take Roads Less Travelled

Pfizer relies on investigators to determine when prioritization recommendations apply, Moderna offers unblinding to everyone.

Placebo-Unblinding Should Be Uniform Across COVID Vaccine Trials, Advisory Committee Says

US FDA’s outside advisors say Moderna should offer vaccine to placebo-arm patients when they are eligible, the same plan adopted for the Pfizer/BioNTech COVID-19 vaccine.

US FDA’s Vaccine Advisory Committee Roster Tweaked For Moderna Review

After the various turnovers, the panel will be one person smaller, and while the agenda includes familiar topics, including maintaining placebo controls after a vaccine is available, the presentation order will be different.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS051363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel